US 12,226,429 B2
Highly active compounds against COVID-19
Jean-Pierre Sommadossi, Boston, MA (US); and Adel Moussa, Burlington, MA (US)
Assigned to Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed by Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed on Jul. 24, 2023, as Appl. No. 18/225,452.
Application 18/225,452 is a continuation of application No. 17/094,541, filed on Nov. 10, 2020, granted, now 11,707,480.
Application 17/094,541 is a continuation of application No. 17/017,443, filed on Sep. 10, 2020, granted, now 10,874,687, issued on Dec. 29, 2020.
Claims priority of provisional application 62/982,670, filed on Feb. 27, 2020.
Claims priority of provisional application 62/994,206, filed on Mar. 24, 2020.
Claims priority of provisional application 63/032,247, filed on May 29, 2020.
Claims priority of provisional application 63/039,352, filed on Jun. 15, 2020.
Claims priority of provisional application 63/040,985, filed on Jun. 18, 2020.
Claims priority of provisional application 63/054,680, filed on Jul. 21, 2020.
Claims priority of provisional application 63/073,328, filed on Sep. 1, 2020.
Prior Publication US 2024/0238324 A1, Jul. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 31/706 (2006.01); A61K 31/7064 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61P 31/14 (2018.01)] 17 Claims
 
1. A method for the treatment of a coronavirus in a human in need thereof comprising administering an effective amount of Compound 1:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.